According to numerous studies, a high prevalence of iron deficiency (ID) with anaemic syndrome and its association with mortality during chronic heart failure (CHF) have been revealed. Ferrocorrection of anaemia during CHF is important both to improve the clinical condition and to optimize the long-term prognosis of patients. However, the pathogenetic justification is the use of agents that have antihypoxic, antioxidant and membrane-stabilizing effects, except iron preparations, and at the same time exert a regulatory effect on the metabolism of physiologically active compounds and improve the functional condition of patients.
Introduction
Today, the question of the importance of iron deficiency (ID) as a new therapeutic goal for reducing symptoms, quality of life (QOL) and prognosis of patients with chronic heart failure (CHF) is rather acute [1, 2] .
The prevalence of anemia as a manifest form of ID of patients with HF reaches about 30 % in outpatient and about 50 % in hospitalized patients [3] . According to the above numbers, it can be concluded that ID is a very common comorbidity of CHF, which is known to be independent of sex, race and left ventricular (LV) ejection fraction (EF) (LVEF) [3] , but is related to age [4] and increase in functional class (FC) of chronic heart failure according to NYHA classification -at FC III to 33 % and at FC IV to 80 % [5, 6] .
Numerous studies aimed at identifying the causes and mechanisms of occurrence of ID with and without anemic syndrome during CHF, have found that proinflammatory activity and anemia of chronic disease (ACD) [7] are the most common causes of anemia of patients with CHF [1] . In other words, ID during CHF is more often functional. Whereas, manifest absolute ID -IDA among the total number of anemic patients with CHF is less common [1] . However, regardless of the variant of iron metabolism disorder that underlies the development of anemia, patients with ID present a significant problem for practical health care since the anemia syndrome during CHF is associated with an increase in mortality and the frequency of hospitalizations of patients [3, 8, 9] . In addition, ID independently of anemia contributes to the development of skeletal muscle dysfunction, which in turn causes a decrease in exercise tolerance (ET) of patients and serves as an independent factor in reducing the QL of patients [10, 11] . When anemia occurs, there are compensatory hemodynamic mechanisms that lead to the progression of HF and consequently further reduce ET and clinical condition of patients [5] .
At the same time, it is known that effective correction of anemic syndrome of patients with CHF improves the condition and clinical prognosis [5] . According to modern approaches to correction of IDA of patients with CHF the most often are used peroral and parenteral ferrocorrection.
However, the modern pharmacological strategy for the treatment of IDA of patients with CHF must take into account, without fail, the nature of metabolic disorders that occur simultaneously with iron metabolism disorders. The pathogenetic justification is the use of agents that have antihypoxic, antioxidant and membrane-stabilizing effects, except iron preparations, and at the same time exert a regulatory effect on the metabolism of physiologically active compounds and improve the functional condition of patients.
The aim of this study was to identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on exercise tolerance of patients with chronic heart failure with reduced ejection fraction of left ventricle with concomitant iron deficiency anemia.
Materials and methods
The study includes 62 patients with CHF with reduced LVEF FC II-III according to NYHA with IDА. Patients with hypertensive and ischemic etiology of HF took part in the study. Among them, 45 (72.6 %) were men and 17 (27.4 %) were women aged 70.0±0.9 years. All patients were hospitalized in the therapeutic departments of the Vinnytsia Regional Clinical Hospital of War Veterans in the period from 2013 to 2017.
The study was conducted with the consent of patients in accordance with the basic bioeth- For the diagnosis of IDА, the following criteria were used: 1) a decrease Hgb level in men <130 g/l and in women <120 g/l; 2) SI in women <11.5 µmol/l and in men <13.0 µmol/l; 3) ferritin level <100 ng/ml. Anemia of mild degree was determined in the case of Hgb values -110-119 g/l for women and 110-129 g/l for men, moderate -within 109-80 g/l and severe -<80 g/l, as for women and for men (WHO, 2011). Only patients with mild and moderate anemia were included in the study.
To determine the changes of effort tolerance (ET) in patients during treatment, the dynamics analysis of the covered six-minute walk test distance was conducted.
Medicine and Dentistry
According to the study design, all patients received standard therapy indicated by modern ESC recommendations, taking into account ischemic and hypertensive etiology of CHF and comorbid conditions, such as atrial fibrillation.
In order to avoid the possible impact of standard treatment on the results of ferrotherapy, standard drug regimens were prescribed. Drug dosages were selected individually, taking into account the patients' clinical condition.
Two study groups were formed: in addition to the standard therapy, the patients in the 1st group (n=32) were prescribed oral ferrous sulfate in a dose of 320 mg, equivalent to 100 mg of bivalent iron and 60 mg of ascorbic acid 2 tablets per day for 6 months; the patients in the 2nd group (n=30) received the standard therapy of CHF and not only iron, but also L-carnitine.
The groups of patients were compared by gender, age, main clinical characteristics and treatment ( Table 1 ). 
Note: ACE inhibitors -angiotensin converting enzyme inhibitors, ARBs -angiotensin II receptor blockers, β-blockers -beta-adrenergic blocking agents, ASA -acetylsalicylic acid, TD/TPD -thiazide and thiazide-like diuretics
Statistical processing of the obtained results was performed using the software package Microsoft Office Excel and Statistica. Due to abnormal distribution of data, the obtained measurements are presented as a median (lower, upper quartile). The statistical significance of the difference in the measured parameters among the groups was calculated according to Kruskal-Wallis ANOVA & Median test for all groups criterion, and the difference between the results of 6-month treatment and the output values was calculated according to Wilcoxon matched pairs test criterion. The difference in the frequency of signs (%) was calculated by the χ 2 criterion. The difference was considered reliable at p<0.05.
Results
The use of two variants of ferrocorrection as an application to the standard treatment of CHF among the total number of studied patients with IDA indicates the sufficient effect both to eliminate the signs of anemia and to eliminate ID. A comparative analysis of the clinical and hematological effectiveness of 6-month oral ferrotherapy with iron sulfate and the effectiveness of combined ferro-and metabolic therapy showed no difference since the intergroup distribution of patients with different hematological evolution in the two treatment groups did not differ (p=0.83) ( Table 2 ). In both groups, the percentage of patients with eliminated IDA was predominant. Comparison of the studied laboratory parameters of patients with IDA after 6 months with different options for additional treatment revealed no difference in the increase in hematological parameters, except for the levels of Hct, which were higher for patients who received additional L-carnitine. In addition, in patients receiving metabolic therapy, there was a tendency to a greater increase in Hgb and Rbc ( Table 3) . Continuation of Table 3  1  2  3  4  5  6 The analysis of the dynamics of the passed test distance with a 6-minute walk in 32 patients with IDA on the background of standard treatment and additional ferrotherapy after 6 months showed an increase of the actual distance by 8.9 % (from 249.4 to 272.3 m, p<0.0001) (Fig. 1) . The analysis of changes in the value of travelled distance among patients with IDA who received combined 6-month ferrotherapy with L-carnitine also revealed a significant positive trend. In addition, the value obtained was significantly higher compared to the results of patients with only additional ferrotherapy, an increase of 19.4 % (from 259.5 to 304.5 m, p <0.0001). Fig. 1 . The dynamics of the covered six-minute walk test distance in patients with CHF with reduced LVEF and IDA on the background of the treatment: p id-6 -reliability of differences between initial distance and post-treatment distance; p id, 1-2 -reliability of initial distance differences between two treatment groups; p 6, 1-2 -reliability of distance differences after 6 months of observations between two treatment groups; p Δ, 1-2 -reliability of changes difference between two treatment groups Analysis of the distribution of CHF FC by NYHA among all patients with IDA showed a significant positive dynamics and reduction of FC by 1 class during treatment compared to the initial distribution in 14 (22.6 %) patients (p<0.0001).
Evaluation of changes in FC dynamics on the background of different treatment revealed a tendency (p<0.08) to increase the number of cases of reduction of FC CHF by NYHA in pa- 
Discussion
Taking into account the disadvantages of oral ferrocorrection -slow absorption in the gastrointestinal tract and its decreased level in conditions of minimal possible inflammation in case of CHF and due to blood congestion, in order to improve patients' physical functioning and general condition, oral ferrotherapy in patients with CHF and concomitant IDA was prolonged in our study. In our study, the obtained data show that hematological indices dynamics in patients who received 6-month ferrotherapy as markers of ferrocorrection efficacy, demonstrated an increase in all parameters and corresponding normalization of iron metabolism indices and to eliminate the signs of anemia in most cases. Thus, it can be argued that ferrotherapy with iron sulfate at the stage of iron deficiency anemia in patients with heart failure with reduced left ventricular ejection fraction for a period of 6 months is effective. In addition, positive hematologic dynamics was accompanied by a major improvement in effort tolerance indices. Because ID, even in the absence of anemia, is a factor of a decrease of physical capacity and quality of life [12] and medicated correction of ID in case of CHF brings positive changes in patients' condition.
However, long-term oral ferrotherapy can only be used in patients with absolute ID. IDА is caused by the multifactorial depletion of iron in the body and the main way of its correction is the use of oral or intravenous iron. Hepcidin function to block intestinal iron absorption and iron release from the mononuclear-phagocyte system, which occur due to activation of proinflammatory cytokines, have an impact on the development of ACD as a functional ID. Therefore, the use of oral iron supplements in this type of ID is not effective, and moreover, dangerous due to possible occurrence of hemosiderosis [1] . Therefore, for the effective treatment of patients with CHF and iron deficiency with anemic syndrome, it is necessary to differentiate the variant of iron metabolism by biochemical parameters.
L-carnitine is a vitamin-like and modified amino acid that plays an important role in supporting the body's metabolic activities. There is growing evidence that high concentrations of L-carnitine provide beneficial effects in various diseases such as coronary artery disease, congestive heart failure, peripheral vascular diseases, type 2 diabetes, dyslipidemia, and hypertension [13] [14] [15] [16] . However, as a treatment of heart failure, L-carnitine has not been recommended in patients with current or prior symptoms of heart failure with reduced ejection fraction and heart failure with preserved ejection fraction in the American guideline [17, 18] . The recommendation of nutritional supplements has not been proposed in the European guideline [19] .
Our study demonstrated that despite the same hematological efficacy, oral ferrotherapy and ferrotherapy in combination with the use of L-carnitine in patients with CHF with reduced LVEF and concomitant IDA have a positive clinical efficacy in relation to the physical ability of patients. However, the use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase in ET, compared with using only iron sulfate ferrocorrection.
Thus confirmed that L-carnitine represents a safe and effective adjuvant therapy which, by increasing high energy phosphate for systolic function, may have a synergistic effect with other drugs [12, 20] . L-carnitine treatment in CHF patients may improve clinical symptoms and the physical capacity, which is particularly relevant for anemic patients. Therefore, the proposed treatment regimen may be recommended for use as additional treatment for patients with chronic heart failure with reduced left ventricular ejection fraction and concomitant iron deficiency anemia.
Limitations of the study. For patients with CH and iron deficiency, it is necessary to determine its type. It can be diagnosed only by determining the biochemical parameters of iron metabolism that is not routinely used. However, this is a way to help determine an effective treatment method.
Prospects for further research. Because the use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase in ET compared with using only iron sulfate ferrocorrection, there is a need to identify the effect of combined use of ferrotherapy with L-carnitine on others clinical and instrumental parameters of patients with CHF with reduced LVEF. Medicine and Dentistry
Conclusions
The use of oral 6-month ferrotherapy and 6-month ferrotherapy in combination with L-carnitine in the treatment of CHF with reduced EF of LV with concomitant IDA eliminated anemia in 87.5 % and 90 % of patients, and iron deficiency in 68.8 % and 76.7 %, respectively. Which in turn allows us to attest to the sufficient effect of the two options for additional treatment of CHF with concomitant IDA, both to eliminate the signs of anemia and to eliminate ID.
Despite the same hematological efficacy, oral ferrotherapy and ferrotherapy in combination with the use of L-carnitine as adjunct options to the standard treatment of CHF with reduced LVEF with concomitant IDA have a positive but different clinical efficacy in relation to the physical ability of patients.
The use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase in ET, which is reflected in a significantly longer test distance with a 6-minute walk and greater frequency of decrease of FC of HF among patients, compared with using only iron sulfate ferrocorrection.
